Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
The first FDA-cleared device that supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our five FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without additional equipment, procedures or radiation dose.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
In its endeavor to expand access to AI for lung cancer detection, CARPL.ai is proud to announce its partnership with Riverain Technologies with the addition of ClearRead™ CT and ClearRead Xray.
Lung cancer is one of the most common cancers worldwide, and its early detection is critical to improving patient outcomes. AI is transforming lung cancer screening, and giving healthcare providers access to the best AI solutions across the globe remains our mission at CARPL.
Today marks yet another milestone towards reaching this goal, as CARPL.ai partners with Riverain Technologies, a global leader in AI-powered thoracic imaging, to bring their ClearRead AI solutions to the CARPL marketplace. Riverain’s FDA-cleared ClearRead CT and ClearRead Xray solutions improve nodule detection, increase efficiency, and quantify coronary artery calcification (CAC) on ungated CT exams. Used globally in 20+ countries, ClearRead solutions are great additions to lung cancer screening programs or for incidental nodule and CAC detection and quantification.
Now available through the CARPL marketplace, Riverain’s solutions will help radiologists to:
• Identify lung nodules earlier by enhancing visibility and reducing distracting structures;
• Reduce missed nodules, leading to more confident diagnoses and improved patient outcomes;
•Quantify coronary artery calcification on every ungated chest CT for an opportunistic approach to heart health;
• Improve efficiency with automatic segmentation, measuring, comparison with prior exams, and reporting integration seamlessly integrated into their existing RIS-PACS.
About CARPL.ai
With CARPL’s vendor-neutral marketplace, radiologists can now access Riverain’s AI solutions alongside 160+ other applications, enabling them to evaluate and implement the best AI solutions for their practice—all within a single platform! For more information, visit www.carpl.ai
About Riverain Technologies
Riverain Technologies is dedicated to transforming the field of radiology by addressing and eliminating delayed cardiothoracic diagnoses. As relentless innovators, Riverain empowers healthcare providers by streamlining diagnostic workflows, enhancing detection accuracy, and ultimately improving patient outcomes. For more information: https://www.riveraintech.com/
Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
